| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Syringetine-3-glucoside targets free radicals and oxidative stress. As a flavonol glycoside, it exhibits free radical scavenging activity, although relatively weak compared to other antioxidants. Its antioxidant activity is mediated through its ability to donate hydrogen atoms or electrons to neutralize free radicals such as DPPH and ABTS. The glycoside moiety may affect its antioxidant potency compared to the aglycone. Its biological activities are primarily related to its potential to protect cells from oxidative damage. However, detailed target information for Syringetine-3-glucoside specifically is limited in the available literature.
|
|---|---|
| ln Vitro |
In vitro, Syringetine-3-glucoside displays relatively weak DPPH and ABTS free radical scavenging activity. Its antioxidant activity is typically assessed using standard cell-free assays. As a flavonol glycoside, it may also have other biological activities such as anti-inflammatory or enzyme inhibitory effects, although these are less extensively documented for this specific compound. Its weak antioxidant activity makes it less potent than some other flavonoids, but it remains a compound of interest for natural product chemistry research.
|
| ln Vivo |
In vivo studies of Syringetine-3-glucoside are not extensively documented. As a flavonol glycoside with weak antioxidant activity, it may have potential for studying oxidative stress-related conditions. However, comprehensive in vivo efficacy and safety data are limited. The compound is primarily used in phytochemical and natural product chemistry research. Further studies are needed to fully characterize its in vivo biological activity and therapeutic potential. The compound is intended for research use only and not for human therapeutic applications.
|
| Enzyme Assay |
For in vitro biochemical assays, Syringetine-3-glucoside is evaluated for its antioxidant activity. Free radical scavenging activity is measured using DPPH and ABTS assays, determining IC50 or EC50 values. Total antioxidant capacity can be assessed using FRAP or ORAC assays. Enzyme inhibition studies can be performed to evaluate effects on specific targets. These cell-free assays help characterize the compound's antioxidant activity and mechanism of action.
|
| Cell Assay |
In vitro cellular assays for Syringetine-3-glucoside are performed using various cell types including normal cells and cancer cells. Cells are cultured in standard media and treated with the compound at various concentrations. Antioxidant activity is assessed by measuring ROS levels using fluorescent probes in cells exposed to oxidative stress. Cell viability is assessed using MTT or trypan blue exclusion assays. These cellular assays help validate the compound's antioxidant activity and potential cytoprotective effects.
|
| Animal Protocol |
In vivo animal experiments with Syringetine-3-glucoside are not extensively documented. As a flavonol glycoside with antioxidant activity, it could be studied in models of oxidative stress-related diseases. Administration routes would include oral gavage, intraperitoneal injection, or intravenous injection. Efficacy endpoints would depend on the specific disease model and could include oxidative stress markers and disease severity. Researchers should consult the primary literature for any available in vivo protocols and data.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Syringetine-3-glucoside are not extensively documented. As a flavonol glycoside with a molecular weight of 508.43, it is expected to have limited oral bioavailability. The compound may be metabolized by intestinal enzymes to release the aglycone. Detailed PK parameters such as half-life, Cmax, Tmax, AUC, and protein binding are not available in the literature. The compound should be stored under recommended conditions to maintain stability.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Syringetine-3-glucoside is not extensively characterized. As a natural flavonol glycoside, it is generally considered to have a favorable safety profile, but comprehensive toxicity studies are limited. The compound is intended for research use only and not for human therapeutic applications. Researchers should follow standard laboratory safety practices when handling Syringetine-3-glucoside.
|
| References | |
| Additional Infomation |
Eugenin-3-O-glucoside is a glycoside belonging to the flavonoid class of compounds. It has been reported that eugenin-3-O-glucoside is found in European spruce, red arboreum, and other organisms with relevant data.
Syringetine-3-glucoside is a valuable research tool for studying flavonol glycosides and antioxidant activity. Its structure makes it useful for investigating the relationship between glycosylation and antioxidant activity in flavonoids. The compound can be employed in studies on natural product chemistry, phytochemistry, and the development of antioxidant agents. Its presence in various plants makes it relevant for research on plant secondary metabolites and their biological activities. |
| Molecular Formula |
C23H24O13
|
|---|---|
| Molecular Weight |
508.42886
|
| Exact Mass |
508.122
|
| CAS # |
40039-49-4
|
| PubChem CID |
5321577
|
| Appearance |
Light yellow to yellow solid
|
| Density |
1.73g/cm3
|
| Boiling Point |
850.6ºC at 760 mmHg
|
| Melting Point |
250ºC (dec.)
|
| Flash Point |
292.9ºC
|
| Index of Refraction |
1.729
|
| LogP |
0.7
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
36
|
| Complexity |
806
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
COC1=C(C(=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)OC)O
|
| InChi Key |
JMFWYRWPJVEZPV-AVGVHVDKSA-N
|
| InChi Code |
InChI=1S/C23H24O13/c1-32-12-3-8(4-13(33-2)16(12)27)21-22(18(29)15-10(26)5-9(25)6-11(15)34-21)36-23-20(31)19(30)17(28)14(7-24)35-23/h3-6,14,17,19-20,23-28,30-31H,7H2,1-2H3/t14-,17-,19+,20-,23+/m1/s1
|
| Chemical Name |
5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9668 mL | 9.8342 mL | 19.6684 mL | |
| 5 mM | 0.3934 mL | 1.9668 mL | 3.9337 mL | |
| 10 mM | 0.1967 mL | 0.9834 mL | 1.9668 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
